Tirzepatide to slow biological aging
Treatments studied
This study tests whether the medication tirzepatide (a drug used for diabetes and weight loss) can slow the biological aging process in adults aged 55 to 70 who have excess weight. You would take the medication as a weekly injection for a set period, and researchers will monitor changes in your body's health markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 70 years old.
- Your BMI is 30 or higher, or 27 or higher if you also have a weight-related condition like high blood pressure or diabetes.
- Your BMI is not over 35.
- You are not currently taking insulin or any prescription weight-loss medications.
- You have not had weight-loss surgery, and you are not planning to start a strict diet or exercise program during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the drug tirzepatide can improve muscle and blood vessel health in older adults with obesity. You may be eligible if you are 50 or older, have a BMI between 30 and 40, and do not have diabetes.
This trial tests whether a weight-loss medicine called tirzepatide can slow biological aging and improve metabolism in people with HIV who are already on effective treatment. It may help you reduce weight and possibly reverse some signs of aging.
This trial tests if two newer weight-loss medications, semaglutide and tirzepatide, can help slow the aging process in adults with obesity. It compares the drugs to each other and to a placebo to see which might offer anti-aging benefits beyond weight loss.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
Hear when a new Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.